Equity Overview
Price & Market Data
Price: $1.52
Daily Change: +$0.04 / 2.63%
Daily Range: $1.40 - $1.54
Market Cap: $2,845,517
Daily Volume: 107,213
Performance Metrics
1 Week: -6.25%
1 Month: -44.99%
3 Months: -59.93%
6 Months: -70.71%
1 Year: -90.83%
YTD: -91.14%
Company Details
Employees: 12
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder PTSD, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company has a strategic collaboration with PsyLabs to produce Ibogaine. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc.